Altimmune, Inc. Stock News

GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association's (ADA) 85th Scientific Sessions, to be held in Chicago, IL f...

I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in multiple metabolic diseases, making it an attractive acquisition target. VKTX's VK2735 offers strong weight loss efficacy and dual formulation flexibility, but faces tough competition and lacks cle...

ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, although pemvidutide will be compared to other competitors. ALT has also initiated a trial of pemvidutide in alcohol use disorder, with a trial in alcohol liver disease set to start in Q3'25.

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pem...

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:

Altimmune, Inc. (NASDAQ:ALT ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Greg Weaver - Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Liisa Bayk...

GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE: HTGC), a leader in debt financing for life science companies, for up to $100 million in a cre...

Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with He...